News
Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 30, 2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
-
May 28, 2019Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 -
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
-
May 28, 2019
NEW YORK, NY, May 28, 2019, -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,...
-
May 13, 2019BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON, May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,...
-
May 10, 2019BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate UpdateHighlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial;
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
Tools
Investors
- Overview
- News
- Events & Presentations
- Stock Information
- Financial Reports & Filings
- Corporate Governance